Clinical trial NCT00637702: A Study of ARRY-334543 in Patients With Advanced Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Advanced Cancer
Lead sponsor: Array BioPharma
Sponsor class: INDUSTRY
First posted: 2008-03-18
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a Phase 1 study during which patients with advanced solid tumors will receive a new formulation of investigational study drug ARRY-334543. Patients will receive increasing doses of study drug in order to achieve the highest dose possible that will not cause unacceptable side effects. The patients will be followed to see what side effects and effectiveness the study drug has, if any, in treating the cancer. In addition, the effect of food on the new formulation will be evaluated. Approximately 24 patients from Canada will be enrolled in this study (Active, not recruiting).


Eligibility criteria: Key Inclusion Criteria:

* Histological or cytological evidence of malignancy.
* Patients with advanced solid tumors who are no longer candidates for standard therapy, have no standard therapy available, or choose not to pursue standard therapy.
* Cardiac ejection fraction ≥ 50% by echocardiogram (ECHO) or multiple gated acquisition (MUGA).
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2.
* Additional criteria exist.

Key Exclusion Criteria:

* Uncontrolled brain metastases (if a patient has brain metastases and is on steroids, the steroid dose must be stable for at least 30 days).
* Use of an investigational medication or device within 30 days prior to first dose of study drug.
* Major surgery within 30 days prior to first dose of study drug.
* Radiotherapy or chemotherapy within 28 days prior to first dose of study drug (not including palliative radiotherapy at focal sites).
* Active, uncontrolled infection requiring systemic antibiotic therapy or other serious underlying medical condition which would impair the ability of the patient to receive protocol treatment.
* Pregnancy or lactation.
* Known positive serology for the human immunodeficiency virus (HIV), 'active' hepatitis B and/or hepatitis C.
* Additional criteria exist.

Primary outcomes:
measure: Characterize the safety profile of the new formulation of study drug in terms of adverse events, clinical laboratory tests and electrocardiograms.
timeFrame: Duration of study
measure: Establish the maximum tolerated dose (MTD) of the new formulation of study drug.
timeFrame: Duration of study
measure: Characterize the pharmacokinetics (PK) of the new formulation of study drug (in terms of plasma concentrations) when administered in a fed versus fasted state.
timeFrame: Day 1 and Day 8
measure: Assess the exposure of the new formulation of study drug in terms of plasma concentrations.
timeFrame: Duration of study
Secondary outcomes:
measure: Assess the efficacy of the new formulation of study drug in terms of tumor dimension assessment.
timeFrame: Duration of study
Other outcomes:
Locations:
city: Hamilton
country: Canada
facility: Juravinski Cancer Center at Hamilton Heath Sciences
state: Ontario
city: Ottawa
country: Canada
facility: Ottawa Hospital Cancer Centre
state: Ontario
Study officials:
affiliation: Pfizer
name: Pizer CT.gov Call Center
role: STUDY_DIRECTOR
References: